Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)

Clinical trial NCT05582265 · RECRUITING

Trial details

NCT number: NCT05582265
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Head and Neck Squamous Cell Carcinomas

Start date: 2022-10-28
Primary completion: 2028-10-01
Enrollment: 537

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.